Overview
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Description
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Eligibility
Inclusion Criteria:
- Male or female adult ≥ 18 years of age;
- Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:
- EASI score of 16 or greater,
- IGA score of 3 or greater
- BSA of 10% or greater,
Exclusion Criteria:
- Subjects with previous exposure to dupilumab.
- Known or suspected hypersensitivity to dupilumab or any of its excipients.
- History of photosensitivity.